Skip to main content
Cellid Co., Ltd. logo

Cellid Co., Ltd. — Investor Relations & Filings

Ticker · 299660 ISIN · KR7299660001 KO Manufacturing
Open in API
Filings indexed 393 across all filing types
Latest filing 2023-06-16 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 299660

About Cellid Co., Ltd.

http://www.cellid.co.kr

Cellid Co., Ltd. is a research and development biotechnology company focused on immunotherapeutic vaccines. The company's activities are centered on two proprietary technology platforms: CeliVax for anti-cancer immunotherapy and an adenovirus vector platform for infectious disease vaccines. The CeliVax platform is used to develop personalized vaccines that utilize a patient's own B cells and monocytes to target specific cancer antigens. The adenovirus vector platform enables the rapid development of safe, non-replicating viral vector vaccines, with a key application being its COVID-19 vaccine candidate. Cellid's pipeline is built upon these core technologies to address unmet medical needs in oncology and virology.

Recent filings

Filing Released Lang Actions
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Amendment Report) to a previously filed stock option grant. It details changes to the number of shares granted and the number of recipients due to employee departures. In the context of Korean regulatory filings (DART system), this type of disclosure regarding stock options and capital changes falls under general regulatory filings that do not fit into specific categories like M&A or Annual Reports, and is best classified as a Regulatory Filing (RNS).
2023-06-16 Korean
[기재정정]주식매수선택권부여에관한신고
Share Issue/Capital Change Classification · 100% confidence The document is a formal regulatory filing titled '주식매수선택권 부여에 관한 신고' (Report on Granting of Stock Options) and specifically functions as a '정정신고' (Correction Report) for a previously filed stock option grant. It details changes to the number of recipients and the number of shares granted due to employee departures. This type of filing, which concerns changes to capital structure and equity-based compensation, falls under the category of 'Share Issue/Capital Change' (SHA) as it relates to the issuance and modification of stock-based instruments.
2023-06-16 Korean
주요사항보고서(유상증자결정)
Share Issue/Capital Change Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) from the company Cellid, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It outlines the number of new shares, the purpose of the capital raise, the allocation method, and the subscription schedule. This falls under the category of announcements regarding new share issues and capital changes.
2023-06-16 Korean
증권신고서(지분증권) (2023.08)
Capital/Financing Update Classification · 100% confidence The document is a '증권신고서' (Securities Registration Statement) filed with the Financial Services Commission (FSC) in South Korea. It details a capital increase (share issuance) by Cellid Co., Ltd., including information on the offering, investment risks, and financial status. This type of document is a formal regulatory filing for capital raising, which falls under the 'Capital/Financing Update' category.
2023-06-16 Korean
투자판단관련주요경영사항(임상시험계획승인신청)(COVID-19 예방 백신 AdCLD-CoV19-1 OMI의 제3상 임상시험 계획(IND) 신청)
Regulatory Filings Classification · 100% confidence The document is a regulatory filing from a Korean company (Cellid) regarding the submission of a Phase 3 clinical trial application (IND) for a COVID-19 vaccine. It follows the standard format for 'Major Management Matters' (투자판단 관련 주요경영사항) required by the Korea Exchange (KRX). Since it is a specific regulatory disclosure regarding clinical trial status and does not fit into categories like financial reports, dividends, or board changes, it is classified as a Regulatory Filing (RNS).
2023-05-23 Korean
분기보고서 (2023.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Cellid' (주식회사 셀리드) covering the period from January 1, 2023, to March 31, 2023. It contains detailed financial information, business operations, and management discussions, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2023
2023-05-15 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.